TransMedics Group financials
$82.73−3.00%
Close Sep 28, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $189.9M | $173.9M | $160.8M | $143.8M | $157.4M | $143.5M | $121.6M | $108.8M | $114.3M | $96.8M | $81.2M | $66.4M |
| Gross profit | $113.2M | $101.2M | $93.4M | $84.6M | $96.6M | $88.2M | $72.0M | $60.8M | $69.3M | $60.0M | $47.9M | $40.7M |
| Gross margin | 59.6% | 58.2% | 58.1% | 58.8% | 61.4% | 61.5% | 59.2% | 55.9% | 60.6% | 61.9% | 59.0% | 61.2% |
| Operating income | $23.7M | $13.3M | $21.3M | $23.3M | $36.6M | $27.4M | $8.6M | $3.9M | $12.5M | $12.4M | $2.6M | -$28.3M |
| Net income | $14.7M | $7.3M | $105.4M | $24.3M | $34.9M | $25.7M | $6.9M | $4.2M | $12.2M | $12.2M | $4.0M | -$25.4M |
| Net margin | 7.7% | 4.2% | 65.6% | 16.9% | 22.2% | 17.9% | 5.6% | 3.9% | 10.7% | 12.6% | 5.0% | −38.3% |
| Diluted EPS | $0.41 | $0.20 | $2.57 | $0.66 | $0.92 | $0.70 | $0.19 | $0.12 | $0.35 | $0.35 | $0.12 | $-0.78 |
| EBITDA | $34.0M | $25.2M | $28.7M | $30.1M | $43.3M | $33.6M | $14.3M | $9.1M | $17.1M | $16.7M | $2.6M | -$26.4M |
| Operating cash flow | $17.3M | $24.5M | $34.5M | $69.6M | $91.6M | -$2.9M | $19.7M | $6.9M | $25.7M | -$3.4M | $8.3M | -$6.9M |
| Free cash flow | $10.2M | -$12.1M | $19.0M | $61.9M | $82.5M | -$29.9M | $6.1M | -$41.3M | $2.0M | -$47.6M | -$6.3M | -$141.8M |
| Diluted shares | 40.7M | 36.2M | 40.9M | 40.7M | 40.6M | 39.9M | 35.2M | 35.7M | 35.3M | 34.7M | 32.6M | 32.6M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $472.7M | $461.7M | $488.4M | $466.2M | $400.6M | $310.1M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $861.7M | $857.0M | $512.4M | $511.7M | $510.9M | $510.1M |
| Total assets | $1.46B | $1.43B | $1.07B | $946.0M | $890.5M | $837.5M |
| Total liabilities | $946.3M | $940.8M | $595.3M | $590.8M | $572.4M | $571.2M |
| Shareholders' equity | $518.1M | $494.0M | $473.1M | $355.2M | $318.1M | $266.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology